This company has been marked as potentially delisted and may not be actively trading. NASDAQ:BIVV Bioverativ (BIVV) Stock Price, News & Analysis Add Share Share Stock Analysis Stock AnalysisBuy This Stock About Bioverativ Stock (NASDAQ:BIVV) Get Bioverativ alerts:Sign Up Key Stats Today's Range$104.98▼$104.9850-Day Range$104.98▼$104.9852-Week Range$48.14▼$105.01VolumeN/AAverage Volume3.03 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Bioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person's blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN). Read More Receive BIVV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bioverativ and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BIVV Stock News HeadlinesBioverativ Aktie | BIVV Kurs | Realtime - Investing.comJuly 2, 2025 | de.investing.comBiogen Inc 0R1B Stock QuoteMay 25, 2023 | morningstar.comMWhy This Titanium Explorer Caught Rio Tinto’s EyeAs U.S. defense spending crosses $1 trillion, drones, hypersonics, and next-gen aerospace are taking center stage. Behind them? Titanium - lightweight, nearly as strong as steel, and essential to the F-35 Raptor, missile systems, and long-endurance UAVs. Yet the U.S. imports 91% of it... mostly from China, Russia, and Kazakhstan. This could be one of North America's most strategically important new sources of titaniumOctober 10 at 2:00 AM | Capital Trends (Ad)EDU Crosses Above Average Analyst TargetApril 1, 2023 | nasdaq.comBioverativ Makes Splash in Trading Debut, Gaining 18% on Day OneDecember 17, 2022 | thestreet.comAmarin Stock: Potential Risks And Rewards (NASDAQ:AMRN) - Seeking AlphaAugust 14, 2022 | seekingalpha.comManagement to host conference call today at 4:30 p.m. ET - Form 8-K - Marketscreener.comAugust 5, 2022 | marketscreener.comMCuris Reports Second Quarter 2022 Financial Results and Business Update - Yahoo FinanceAugust 4, 2022 | finance.yahoo.comSee More Headlines BIVV Stock Analysis - Frequently Asked Questions How were Bioverativ's earnings last quarter? Bioverativ Inc. (NASDAQ:BIVV) released its quarterly earnings data on Thursday, October, 26th. The biotechnology company reported $0.80 EPS for the quarter, beating the consensus estimate of $0.55 by $0.25. The firm's quarterly revenue was up 27.2% on a year-over-year basis. What other stocks do shareholders of Bioverativ own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bioverativ investors own include Rexford Industrial Realty (REXR), Biogen (BIIB), Spark Therapeutics (ONCE), Bristol Myers Squibb (BMY), Phillips 66 (PSX), Gilead Sciences (GILD) and Marinus Pharmaceuticals (MRNS). Company Calendar Last Earnings10/26/2017Today10/10/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:BIVV CIK1681689 Webwww.bioverativ.com Phone+1-781-6634400FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:BIVV) was last updated on 10/10/2025 by MarketBeat.com Staff From Our Partners"I'm risking my reputation on this"The Fed rate cut truth they don't want you to know The Fed's 25 basis point cut isn't just monetary policy…...Crypto 101 Media | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredElon Warns “America Is Broke”. Trump’s Plan Inside.For the everyday American who's worked hard to build their nest egg, Trump preserved a IRS loophole that allow...American Hartford Gold | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioverativ Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioverativ With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.